1. At a Glance
When a company with a market capitalization of just ₹105 crore decides to completely discard its core manufacturing operations, corporate observers lean in. Par Drugs & Chemicals Ltd has served up a corporate thriller that changes the investment thesis from a typical smallcap pharma play into a complex governance puzzle.
The headline figures for the full financial year ending March 31, 2026, show a business operating in complete stasis. Annual revenue from operations edged up marginally to ₹103.66 crore compared to ₹100.97 crore in the previous fiscal year. Net profit followed a similar flat trajectory, arriving at ₹13.11 crore against ₹13.36 crore in FY25.
On the surface, this looks like a stable, debt-free enterprise operating at a low price-to-earnings multiple of 8.03. However, look closer at the final quarter of FY26. Sales for Q4 FY26 collapsed by 33.16% sequentially to ₹19.61 crore from ₹29.34 crore in Q3 FY26. Net profit for the final quarter was battered even harder, plunging 82.29% quarter-on-quarter to just ₹0.85 crore from ₹4.80 crore.
The real story lies hidden in the regulatory announcements accompanying these numbers. The board of directors had previously orchestrated a slump sale of its entire pharmaceutical business undertaking to a related party named Phal-Jig Fine Chemicals Private Limited for a transaction value of ₹95 crore. Along with this sale, an Extraordinary General Meeting approved a total transformation of the corporate identity, altering the main objects of the company away from active pharmaceutical ingredients and into real estate, capital markets, and clean energy ventures.
The market was bracing for this transition, but a major regulatory hurdle has appeared. On May 14, 2026, alongside the annual results, the board revealed that the Securities and Exchange Board of India issued an ex-parte interim order and subsequent confirmatory order that actively restrains the completion of this business transfer arrangement. SEBI has stepped in, appointed independent valuers and fairness opinion advisors, and frozen the transaction. The core asset sale is locked in regulatory limbo, leaving public shareholders holding equity in a company caught between a stalled exit from pharma and an unexecuted entry into real estate.
2. Introduction
Par Drugs & Chemicals Ltd, incorporated in 1982, has built its reputation over four decades as a reliable niche manufacturer of Active Pharmaceutical Ingredients and Fine Chemicals. Based out of Bhavnagar in Gujarat, the company established a robust presence in the specialized antacid molecules segment. Operating a primary manufacturing facility at the G.I.D.C. Industrial Estate in Chitra, Bhavnagar, the company commands an annual production capacity of 9,700 metric tons.
Over the years, the company carved out a steady domestic market share alongside a targeted export presence spanning 16 countries, including developed economies like the United Kingdom and Germany. Its client roster features prominent names such as Pfizer Ltd, Cipla Ltd, and United Phosphorus Ltd.
Despite this established corporate history, the operational dynamics over the past three years indicate a business that has hit a growth ceiling. Volume growth has plateaued, and the intense pricing pressures characteristic of the global chemical supply chain have squeezed margins. This stagnation led the promoter group, the Savani family, to initiate a radical change in strategy.
Rather than deploying capital to expand chemical capacities or scale new molecules, management decided to exit the manufacturing sector entirely. This strategy was formalized through an agreement in early 2025 to sell off the existing manufacturing establishment. With SEBI halting the transaction, the company faces an uncertain future. It must manage a deteriorating core business while its legal team challenges regulatory interventions.
3. Business Model – WTF Do They Even Do?
To the casual observer, Par Drugs & Chemicals Ltd looks like a standard pharmaceutical business. It produces the raw active ingredients that give your over-the-counter antacids their therapeutic power. If you have ever consumed a liquid antacid or an effervescent tablet to cure indigestion, you have likely consumed the compound chemistry managed by this company.
The operational portfolio is split into two primary segments: APIs, which account for approximately 57% of historical revenues, and Fine Chemicals, which bring in the remaining 42%. The chemical catalog focuses entirely on metal salts and gels:
- Magnesium Salts: Producing Magnesium Hydroxide, Carbonate, Trisilicate, and specialized oxides used for neutralization in digestive tract treatments.
- Dried Aluminium Hydroxide Gel & Blends: Serving as active medicaments in traditional antacid formulations.
- Specialty Silicates: Sodium Aluminium Silicate and Precipitated Silica, which find utility outside pharma, moving into paper, paints, coatings, cosmetics, and detergents as anti-caking agents.
The core business model relies on bulk B2B manufacturing, importing raw minerals, processing them into high-purity chemicals, and shipping them to domestic formulators (79% of revenue) and international buyers (21%).
The strategic complication is that management no longer wants to run this business. The approved alteration of the Memorandum of Association shifts the company’s objective away from chemical processing and into real estate development, capital market investments, and renewable energy infrastructure. The operational manufacturing engine is being treated as a discontinued asset waiting for clearance, while the corporate shell prepares to manage financial assets and land banks.
4. Financials Overview
The financial performance of Q4 FY26 indicates a business experiencing operational disruption, likely driven by the distractions
